Cenix Begins Building In Vivo Research Operations, Developing siRNA Delivery Tech

The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.